Disease progress mechanism and treatment of heart failure with reduced ejection fraction

VernacularTitle:射血分数减低型心力衰竭的病情进展机制与治疗
Author: Xiao MENG ¹ ; Feng LI
Author Information

1. 哈尔滨医科大学附属第二医院神经内科,黑龙江哈尔滨 150081
Keywords: Heart failure; Angiotensin-converting enzyme inhibitors; Adrenergic beta-antagonists
From: Chinese Journal of cardiovascular Rehabilitation Medicine 2024;33(1):104-107
CountryChina
Language:Chinese
Abstract: Clinically,the condition of heart failure with reduced ejection fraction(HFrEF)is characterized by progressive decline of cardiac function,accompanied by repeated hospitalization,aggravation of symptoms,obvious deterioration of quality of life,and a huge economic burden on patients'family.And as time goes,therapeutic effect of drugs that used to improve prognosis gradually decrease.Even with the use of the most advanced medical measures,the mortality of patients remains rising.Clinically,HFrEF patients are more likely to occur intolerance to neurohormonal drugs,high request dose of diuretics and diuretic-resistant cardiorenal syndrome,thus neurohormonal activation may be a main determining factor of its progression.The present article reviews the disease progress mechanism and therapeutic program of HFrEF.